Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (6): 1079-1085. doi: 10.19723/j.issn.1671-167X.2022.06.004

Previous Articles     Next Articles

Clinical characteristics of patients with rheumatoid arthritis complicated with venous thrombosis of lower extremities

Rui LIU1,Jin-xia ZHAO1,*(),Liang YAN1,2   

  1. 1. Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China
    2. Department of Emergency, Yan'an Branch of Peking University Third Hospital (Traditional Chinese Medicine Hospital of Yan'an), Yan'an 716000, Shaanxi, China
  • Received:2022-07-26 Online:2022-12-18 Published:2022-12-19
  • Contact: Jin-xia ZHAO E-mail:zhao-jinxia@163.com

Abstract:

Objective: To analyze the clinical characteristics of patients with rheumatoid arthritis (RA) complicated with venous thrombosis of lower extremities, and to improve the awareness of this condition. Methods: The clinical and laboratory data of 502 RA patients hospitalized in Department of Rheumatology and Immunology Peking University Third Hospital from November 1, 2013 to December 31, 2020 were collected, retrospective analysis was made on the RA patients who were diagnosed with lower limb vein thrombosis on discharge but hadn't on admission, the patients in this group were defined as thrombosis group, and the other patients without lower limb vein thrombosis were taken as control group. Single factor analysis was conducted between the two groups. Then multivariate Logistic regression analysis was used to analyze the independent risk factors of RA complicated with lower limb venous thrombosis with statistical significance in univariate analysis. Results: There were 34 patients (6.77%) in the thrombosis group and 468 patients (93.23%) in the control group. The age of thrombosis group was 34-86 years (median age was 71 years); 23 were female and 11 were male; there were 20 cases with unilateral lower limb vein thrombosis and 14 cases with bilateral lower limb vein thrombosis; pulmonary embolism in 3 cases (low risk).In the thrombosis group 17 (50.0%) patients were bedridden for more than one week or needed crutches/wheelchairs before admission. 29 cases(85.3%)had large joint involvement of lower extremities, including 22 cases of knee joint involvement, 1 case of hip joint involvement, 2 cases of ankle joint involvement, and 4 cases with both knee and hip joint involvement. In the thrombosis group, the high, middle and low disease activity scores 28(DAS28) were 23 (67.6%), 9 (26.5%) and 2 (5.9%), respectively. There were 21 patients in the thrombosis group had completed thrombosis related examinations, only 4 patients were positive for anti-cardiolipin antibody or anti-β2 glycoprotein 1 antibody or lupus anticoagulant, the rests were all negative. In the thrombosis group, age and platelet (PLT) level were significantly higher than those in the control group [71 (60, 77) years vs. 60 (51, 68) years, Z=-3.873, P < 0.01, (328.53× 109±119.06 × 109) /L vs.(278.68 × 109±104.50 × 109)/L, t=2.660, P < 0.01, respectively]. The proportion of D-Dimer increased in the thrombosis group as well as the positivity rheumatoid factor (RF) was much higher than those in the control group (94.1% vs.66.4%, χ2=11.192, P < 0.01; 85.3% vs.67.1%, χ2=4.852, P < 0.05, respectively). Multivariate Logistic regression analysis showed that age (OR=1.063, 95%CI: 1.026-1.101, P=0.001), D-Dimer increased (OR=4.968, 95%CI: 1.136-21.730, P=0.033) and PLT level (OR=1.004, 95%CI: 1.001-1.007, P=0.022) were the independent risk factors for RA complica-ted with lower extremity venous thrombosis. Conclusion: RA patients have potential risk of thrombosis of lower extremities. For the older age, D-Dimer and PLT elevated, especially those who were bedridden, RF positive and had high disease activity, should be alert to the risk.

Key words: Rheumatoid arthritis, Venous thrombosis, Clinical features

CLC Number: 

  • R593.2

Table 1

General clinical features of RA patients with lower extremity venous thrombosis"

Table 2

Comparison of clinical and laboratory data between RA patients with lower extremity venous thrombosis and without"

Items Thrombosis group Control group t or U value χ2 P
Age/years, M(P25, P75) 71(60, 77) 60(51, 68) -3.873 <0.001#
Male 32.4%(11/34) 25.2%(118/468) 0.846 0.358
Duration/months, M(P25, P75) 36(4, 153) 60(12, 168) -1.162 0.245
Smoking 23.5%(8/34) 17.9%(84/468) 0.660 0.417
ILD 32.4%(11/34) 21.4%(100/468) 2.221 0.136
sSS 11.8%(4/34) 13.1%(61/467) 0.000 >0.999
Anemia 52.9%(18/34) 48.9%(229/468) 0.204 0.652
Knee arthritis 76.5%(26/34) 82.9%(388/468) 0.908 0.341
Hip arthritis 14.7%(5/34) 18.2%(85/468) 0.257 0.612
ANA positive 45.5%(15/33) 52.0%(221/425) 0.525 0.469
RF positive 85.3%(29/34) 67.1%(314/468) 4.852 0.028*
Anti-CCP antibody positive 59.4%(19/32) 70.5%(330/468) 1.763 0.184
HB/(g/L), ${\bar x}$±s 109.53±19.52 111.95±18.30 -0.743 0.458
PLT/(×109/L), ${\bar x}$±s 328.53±119.06 278.68±104.50 2.660 0.008#
ESR/(mm/h), ${\bar x}$±s 48.71±32.06 47.59±30.69 0.205 0.838
CRP/(mg/dL),M(P25, P75) 2.07(0.99,5.88) 2.13(0.71,6.5) -0.154 0.877
IgG/(g/L), ${\bar x}$±s 14.00±5.30 14.57±4.87 -0.647 0.518
IgA/(g/L),${\bar x}$±s 3.29±1.66 3.34±1.95 -0.129 0.897
IgM/(g/L),${\bar x}$±s 1.63±2.18 1.36±0.92 0.715 0.480
D-Dimer increase 94.1%(32/34) 66.4%(293/441) 11.192 0.001#
T-CHO/(mmol/L),${\bar x}$±s 4.22±0.91 4.30±1.03 -0.409 0.683
HDL-C/(mmol/L),${\bar x}$±s 1.11±0.30 1.10±0.32 0.102 0.919
LDH-C/(mmol/L),${\bar x}$±s 2.63±0.77 2.68±0.80 -0.352 0.725
TG/(mmol/L),${\bar x}$±s 1.31±0.52 1.30±0.76 0.058 0.954
DAS28, ${\bar x}$±s 5.62±1.30 5.37±1.48 0.950 0.343

Table 3

Logistic regression analysis of lower extremity venous thrombosis risk factor in RA patients"

Risk factors B SE OR 95%CI P
Age 0.061 0.018 1.063 1.026-1.101 0.001
RF positive 0.948 0.509 2.580 0.952-6.991 0.062
PLT 0.004 0.002 1.004 1.001-1.007 0.022
D-Dimer increase 1.603 0.753 4.968 1.136-21.730 0.033
1 Li LY , Lu N , Avina-Galindo AM , et al. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: A general population-based study[J]. Rheumatology (Oxford), 2021, 60 (1): 188- 195.
doi: 10.1093/rheumatology/keaa262
2 Matta F , Singala R , Yaekoub AY , et al. Risk of venous thromboembolism with rheumatoid arthritis[J]. Thromb Haemost, 2009, 101 (1): 134- 138.
doi: 10.1160/TH08-08-0551
3 Arnett FC , Edworthy SM , Bloch DA , et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988, 31 (3): 315- 324.
doi: 10.1002/art.1780310302
4 Britsemmer K , Ursum J , Gerritsen M , et al. Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: Slight improvement over the 1987 ACR criteria[J]. Ann Rheum Dis, 2011, 70 (8): 1468- 1470.
doi: 10.1136/ard.2010.148619
5 Chopard R , Albertsen IE , Piazza G . Diagnosis and treatment of lower extremity venous thromboembolism: A review[J]. JAMA, 2020, 324 (17): 1765- 1776.
doi: 10.1001/jama.2020.17272
6 Arshad N , Isaksen T , Hansen JB , et al. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population[J]. Eur J Epidemiol, 2017, 32 (4): 299- 305.
doi: 10.1007/s10654-017-0238-y
7 Meng K , Hu X , Peng X , et al. Incidence of venous thromboembolism during pregnancy and the puerperium: A systematic review and meta-analysis[J]. J Matern Fetal Neonatal Med, 2015, 28 (3): 245- 253.
doi: 10.3109/14767058.2014.913130
8 Croles FN , Nasserinejad K , Duvekot JJ , et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and Bayesian meta-analysis[J]. BMJ, 2017, 359, j4452.
9 Crous-Bou M , de Vivo I , Camargo CA Jr. , et al. Interactions of established risk factors and a GWAS-based genetic risk score on the risk of venous thromboembolism[J]. Thromb Haemost, 2016, 116 (4): 705- 713.
10 Heit JA , Ashrani A , Crusan DJ , et al. Reasons for the persistent incidence of venous thromboembolism[J]. ThrombHaemost, 2017, 117 (2): 390- 400.
11 Mean M , Limacher A , Stalder O , et al. Do factor V Leiden and prothrombin G20210A mutations predict recurrent venous thromboembolism in older patients?[J]. Am J Med, 2017, 130 (10): 1220.e17- 1220.e22.
doi: 10.1016/j.amjmed.2017.05.026
12 Gregson J , Kaptoge S , Bolton T , et al. Cardiovascular risk factors associated with venous thromboembolism[J]. JAMA Cardiol, 2019, 4 (2): 163- 173.
doi: 10.1001/jamacardio.2018.4537
13 Peng YH , Lin YS , Chen CH , et al. Type 1 diabetes is associated with an increased risk of venous thromboembolism: A retrospective population-based cohort study[J]. PLoS One, 2020, 15 (1): e0226997.
doi: 10.1371/journal.pone.0226997
14 Riva N , Donadini MP , AgenoW . Epidemiology and pathophysiology of venous thromboembolism: Similarities with atherothrombosis and the role of inflammation[J]. Thromb Haemost, 2015, 113 (6): 1176- 1183.
doi: 10.1160/TH14-06-0563
15 Chen CY , Liao KM . The incidence of deep vein thrombosis in Asian patients with chronic obstructive pulmonary disease[J]. Medicine (Baltimore), 2015, 94 (44): e1741.
doi: 10.1097/MD.0000000000001741
16 Ogdie A , McGill NK , Shin DB , et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A general population-based cohort study[J]. Eur Heart J, 2018, 39 (39): 3608- 3614.
doi: 10.1093/eurheartj/ehx145
17 Lurie JM , Png CYM , Subramaniam S , et al. Virchow's triad in "silent" deep vein thrombosis[J]. J Vasc Surg Venous Lymphat Disord, 2019, 7 (5): 640- 645.
doi: 10.1016/j.jvsv.2019.02.011
18 Broussard J , Berlinger M , Lauret D . A clot (possibly): Due to loss of TNF-α supression[J]. J La State Med Soc, 2017, 169 (2): 52.
19 Mease P , Charles-Schoeman C , Cohen S , et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data[J]. Ann Rheum Dis, 2020, 79 (11): 1400- 1413.
doi: 10.1136/annrheumdis-2019-216761
20 Arshad N , Isaksen T , Hansen JB , et al. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population[J]. Eur J Epidemiol, 2017, 32 (4): 299- 305.
doi: 10.1007/s10654-017-0238-y
[1] Wen-xin CAI,Shi-cheng LI,Yi-ming LIU,Ru-yu LIANG,Jing LI,Jian-ping GUO,Fan-lei HU,Xiao-lin SUN,Chun LI,Xu LIU,Hua YE,Li-zong DENG,Ru LI,Zhan-guo LI. A cross-sectional study on the clinical phenotypes of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1068-1073.
[2] Fang CHENG,Shao-ying YANG,Xing-xing FANG,Xuan WANG,Fu-tao ZHAO. Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1074-1078.
[3] Jing-feng ZHANG,Yin-ji JIN,Hui WEI,Zhong-qiang YAO,Jin-xia ZHAO. Cross-sectional study on quality of life and disease activity of rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1086-1093.
[4] Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620.
[5] GAO Chao,CHEN Li-hong,WANG Li,YAO Hong,HUANG Xiao-wei,JIA Yu-bo,LIU Tian. Validation of the Pollard’s classification criteria (2010) for rheumatoid arthritis patients with fibromyalgia [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 278-282.
[6] ZHANG Lu,HU Xiao-hong,CHEN Cheng,CAI Yue-ming,WANG Qing-wen,ZHAO Jin-xia. Analysis of cervical instability and clinical characteristics in treatment-naive rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1049-1054.
[7] LUO Liang,HUO Wen-gang,ZHANG Qin,LI Chun. Clinical characteristics and risk factors of rheumatoid arthritis with ulcerative keratitis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1032-1036.
[8] ZHONG Hua,XU Li-ling,BAI Ming-xin,SU Yin. Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1026-1031.
[9] LOU Xue,LIAO Li,LI Xing-jun,WANG Nan,LIU Shuang,CUI Ruo-mei,XU Jian. Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1020-1025.
[10] XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272.
[11] CAO Di,WANG Yan,WANG Liu-qing,SUN Xiao-lin,HUANG Fei,MENG Yang,REN Li-li,ZHANG Xue-wu. Expression of plasma Dickkopf-1 in patients with rheumatoid arthritis and its correlation with peripheral blood T cell subsets [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 255-260.
[12] ZHAO Kai,CHANG Zhi-fang,WANG Zhi-hua,PANG Chun-yan,WANG Yong-fu. Therapeutic effect of gene silencing peptidyl arginine deaminase 4 on pulmonary interstitial lesions induced by collagen-induced arthritis mice [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 235-239.
[13] Shi-xiong WEI,Shu-jia LI,Yi LIU. Clinical characteristics and biological treatment of adult patient with juvenile idiopathic arthritis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1014-1022.
[14] Jing-feng ZHANG,Xiu-ling YE,Meng DUAN,Xiao-li ZHOU,Zhong-qiang YAO,Jin-xia ZHAO. Clinical and laboratory characteristics of rheumatoid arthritis with positive antinuclear antibody [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1023-1028.
[15] Guo TANG,Li LONG,Ya-xin HAN,Qing PENG,Jia-jun LIU,Hua SHANG. Clinical characteristics and related factors of rheumatoid arthritis complicated with tuberculosis infection [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1029-1033.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[2] . [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 181 -182 .
[3] . [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 663 -665 .
[4] . [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 39 -42 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(6): 739 -745 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(5): 507 -510 .
[7] . [J]. Journal of Peking University(Health Sciences), 2000, 32(4): 300 .
[8] . [J]. Journal of Peking University(Health Sciences), 2008, 40(2): 146 -150 .
[9] . [J]. Journal of Peking University(Health Sciences), 2008, 40(4): 369 -373 .
[10] . [J]. Journal of Peking University(Health Sciences), 2010, 42(2): 126 -130 .